Atomo Diagnostics (ASX:AT1) has secured a significant new order for its patented Pascal cassette, with strategic partner Lumos Diagnostics (ASX:LDX) placing a US$410,000 (A$630,000) order to support increasing demand for the FebriDx® test in the United States. This is the first Pascal order since Lumos entered a six-year exclusive US distribution agreement with PHASE Scientific,
Read More
The June 2025 quarter CPI data released today were cheered by mortgage holders and share market investors alike. They also put smiles on the faces of Federal politicians on the government side of the house! This because all these groups quickly surmised that these heavily scrutinised price statistics give the Reserve Bank of Australia (RBA)
Read More
AI Gains Ground in Defence Sector As governments increase investment in defence technology, AI-powered tools are carving out a central role in modern military infrastructure. Vection Technologies (ASX:VR1) has secured a $7.3 million extension to an existing defence contract, confirming its foothold in a multi-year digital transformation program for a European client. “This follow-up award
Read More
Calix Limited (ASX:CXL) has taken a significant leap forward in developing Australia’s low-emissions steel value chain, executing a $44.9 million funding agreement with the Australian Renewable Energy Agency (ARENA) to build a ZESTY Green Iron Demonstration Plant. The award marks a turning point for Australia’s role in global decarbonisation efforts, particularly in heavy industry, with
Read More
Online tech retailer Harris Technology (ASX: HT8) has delivered a strong lift in gross product margins across FY25, thanks to a strategic pivot towards refurbished technology products that has produced big growth opportunities for the Company in an otherwise subdued retail market. Despite a drop in total sales revenue for the year ended 30 June
Read More
In a significant move set to reshape rapid diagnostics in the U.S., ASX-listed Lumos Diagnostics (ASX:LDX) has signed an exclusive six-year distribution agreement with PHASE Scientific, valued at up to US$317 million (A$487 million), for the supply of its flagship test, FebriDx®. Targeting a High-Growth Market The deal places Lumos’ FebriDx® at the forefront of
Read More
